Brief: Virios Therapeutics Announces Dosing Of First Patient In Imc-2 Long-Covid Treatment Trial
15/08/2022 12:34
Aug 15 (Reuters) - Virios Therapeutics Inc VIRI.O :
* VIRIOS THERAPEUTICS’ ANNOUNCES DOSING OF FIRST PATIENT IN
IMC-2
LONG-COVID TREATMENT TRIAL
* VIRIOS THERAPEUTICS INC - NEW LONG-COVID RESEARCH PROGRAM
COMPLEMENTS FIBROMYALGIA PHASE 2B CLINICAL RESEARCH PROGRAM
Source text for Eikon: ID:nBwbsTxnza
Further company coverage: VIRI.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Dogwood Therapeutics
See all newsDogwood Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dogwood Therapeutics Q2 net loss widens on higher costs, impairment charge
Brief: Dogwood Therapeutics Q2 EPS USD -0.34
Dogwood Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Dogwood Therapeutics Announces Commencement Of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study